Filing Details

Accession Number:
0001209191-10-044427
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-08-30 16:31:22
Reporting Period:
2010-08-26
Filing Date:
2010-08-30
Accepted Time:
2010-08-30 16:31:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
901219 Human Genome Sciences Inc HGSI In Vitro & In Vivo Diagnostic Substances (2835) 223178468
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1332456 Barry Labinger 14200 Shady Grove Road
Rockville MD 20850
Exec Vp & Cco No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-08-26 13,050 $4.92 13,050 No 4 M Direct
Common Stock Disposition 2010-08-26 13,050 $28.53 0 No 4 S Direct
Common Stock Acquisiton 2010-08-27 16,079 $4.92 16,079 No 4 M Direct
Common Stock Disposition 2010-08-27 16,079 $28.50 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option - Right to Buy Disposition 2010-08-26 13,050 $0.00 13,050 $4.92
Common Stock Employee Stock Option - Right to Buy Disposition 2010-08-27 16,079 $0.00 16,079 $4.92
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
136,950 2018-03-10 No 4 M Direct
120,871 2018-03-10 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Charles Schwab effective 6/16/10.
  2. This transaction was executed in multiple trades at prices ranging from $28.50 to $28.54. The price reported above reflects the weighted average sales price. Upon written request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price is available.
  3. This transaction was executed in multiple trades at prices ranging from $28.50 to $28.51. The price reported above reflects the weighted average sales price. Upon written request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price is available.
  4. One-eigth of the 150,000 options granted on March 10, 2008, vested on the six-month anniversary date (September, 2008) and the remaining options granted vested and continue to vest monthly on a ratable basis for the next 42 months commencing on October 10, 2008.